Japan approves the first iPSC-derived therapy for heart failure, allowing Osaka University to transplant lab-grown cardiac cell sheets onto damaged hearts.
Japan's Ministry of Health, Labour and Welfare has granted conditional approval to the world's first clinical therapy derived from induced pluripotent stem cells (iPSCs) for the treatment of chronic heart failure. The therapy, developed by Dr. Yoshiki Sawa's team at Osaka University, involves transplanting sheets of lab-grown cardiac muscle cells onto damaged hearts to restore contractile function.
The iPSC-derived cardiac cell sheets are manufactured from a bank of clinical-grade iPSCs, eliminating the need for patient-specific cell production. Each sheet contains approximately 100 million cardiomyocytes arranged in a three-dimensional structure that mimics natural heart tissue. During surgery, the sheets are placed directly onto the surface of the damaged heart, where they integrate with existing tissue and begin contracting synchronously.
In the pivotal trial that led to approval, 10 patients with severe ischemic cardiomyopathy received the cell sheet transplant. At one year, cardiac function as measured by left ventricular ejection fraction improved by an average of 10 percentage points. Patients reported significant improvements in exercise capacity and quality of life, with several able to resume activities they had abandoned due to heart failure symptoms.
The approval builds on decades of iPSC research pioneered by Dr. Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012 for discovering how to reprogram adult cells into a pluripotent state. Japan has positioned itself as a global leader in regenerative medicine through its Regenerative Medicine Act, which provides an accelerated regulatory pathway for innovative cell therapies.
The conditional approval allows Osaka University Hospital and five additional designated centers to offer the therapy while post-market surveillance data is collected. The therapy is initially indicated for patients with severe heart failure who are not candidates for heart transplantation, a population with very limited treatment options and poor prognosis.
Cost is a significant consideration. The therapy is priced at approximately 15 million yen ($100,000) per treatment, covered under Japan's national health insurance system. The government views this investment as justified given the high costs of managing end-stage heart failure, including frequent hospitalizations and mechanical circulatory support devices.
International pharmaceutical companies are watching closely. If the post-market surveillance confirms long-term safety and efficacy, the therapy could serve as a model for iPSC-based treatments worldwide. Several companies are already licensing the technology for clinical development in the United States and Europe.